{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T18:39:34Z","timestamp":1649097574848},"reference-count":0,"publisher":"African Journals Online (AJOL)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Afr H. Sci."],"abstract":"<jats:p>Background: Efficacy of elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil (E\/C\/F\/TDF) in treatment-na\u00efve and experienced patients with HIV infection was demonstrated in phase 3 trials. The primary objective of this study was to evaluate effectiveness and safety of E\/C\/F\/TDF in real world settings.&#x0D;\nMethods: Retrospective, observational data collected by the Turkish ACTHIV-IST study group between May 2015 and December 2016 were analysed.&#x0D;\nResults: A total of 387 patients were prescribed E\/C\/F\/TDF; 210 patients with available data at 6th month were eligible; 91.5% were male, and mean age was 35.2 (SD: 10.8) years; 54.0% of males identified themselves as MSM. Sixty-three percent (133) of the study population were treatment-na\u00efve patients, and 37% (77) were treatment experienced. HIV RNA level was below 100 copies\/mL in 78.9% of treatment-na\u00efve patients and 89.9% of treatment experienced patients at month 6. Median increase in CD4 T lymphocyte count was 218 copies\/mL in treatment-na\u00efve patients and remained stable or increased in treatment experienced patients. Adverse events were observed in 15% of the patients, and the regimen was discontinued in only six patients.&#x0D;\nConclusion: Real world data on the effectiveness and safety of E\/C\/F\/TDF is comparable with the phase 3 trial results Adverse events are uncommon and manageable.&#x0D;\nKeywords: Elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate; HIV; effectiveness; safety.<\/jats:p>","DOI":"10.4314\/ahs.v21i4.13","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T10:44:35Z","timestamp":1639737875000},"page":"1593-602","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate single-tablet combination among HIV-infected patients in Turkey: results from a real world setting"],"prefix":"10.4314","volume":"21","author":[{"given":"Bilgul","family":"Mete","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayat","family":"Kumbasar Karaosmanoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Gumuser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Bolukcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Sevgi Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Altuntas Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilgenur","family":"Bilge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilyas","family":"Dokmetas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fehmi","family":"Tabak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2895","published-online":{"date-parts":[[2021,12,14]]},"container-title":["African Health Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/218814\/206429","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/218814\/206429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T10:47:20Z","timestamp":1639738040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/view\/218814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12,15]]}},"URL":"https:\/\/doi.org\/10.4314\/ahs.v21i4.13","relation":{},"ISSN":["1680-6905"],"issn-type":[{"value":"1680-6905","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]}}}